Circadian Rhythm Disorders: Delayed Phase, Shift Work, Jet Lag, and Light Therapy

Introduction

Circadian rhythm sleep-wake disorders (CRSWDs) occur when the internal circadian clock is misaligned with the desired or required sleep-wake schedule, or when the clock oscillates with an abnormal period. The master circadian pacemaker, the suprachiasmatic nucleus (SCN), generates approximately 24-hour rhythms that are entrained to the environment primarily by light.

The Circadian System

Key Components

Component	Function
Suprachiasmatic nucleus (SCN)	Master pacemaker generating approximately 24-hour rhythm
Retinohypothalamic tract (RHT)	Direct pathway from melanopsin-containing ipRGCs in retina to SCN
Pineal gland	Produces melatonin during biological night
Peripheral clocks	Independent oscillators in tissues (liver, muscle, fat, heart) that entrain to SCN
Clock genes	CLOCK, BMAL1, PER (1-3), CRY (1-2) form transcription-translation feedback loops

Phase Response Curve (PRC) to Light

Timing of Light Exposure	Phase Shift Direction	Magnitude
Early biological night (before core body temp minimum)	Phase delay (later)	Up to 2-3 hours
Late biological night (after core body temp minimum)	Phase advance (earlier)	Up to 1-2 hours
Biological day	Minimal or no shift	Small
Core body temperature minimum	Transition point	Maximum sensitivity

Core Body Temperature Minimum

Aspect	Details
Timing	Typically occurs approximately 2-3 hours before habitual wake time
Circadian phase marker	Used to determine timing of light therapy and melatonin
Relationship to melatonin	Melatonin onset occurs approximately 2 hours before temperature starts to drop
Estimation	In normally entrained individuals, temperature minimum occurs approximately at 4-5 AM

Classification of CRSWDs

Disorder	ICD-10	Key Feature
Delayed sleep-wake phase disorder	G47.21	Sleep onset and wake times delayed by 2+ hours relative to desired schedule
Advanced sleep-wake phase disorder	G47.22	Sleep onset and wake times advanced by 2+ hours
Irregular sleep-wake rhythm disorder	G47.23	Disorganized, fragmented sleep without distinct circadian pattern
Non-24-hour sleep-wake rhythm disorder	G47.24	Sleep-wake cycle progressively delays (common in blind individuals)
Shift work disorder	G47.26	Insomnia or excessive sleepiness related to work schedule
Jet lag disorder	G47.25	Transient misalignment from rapid travel across time zones

Delayed Sleep-Wake Phase Disorder (DSWPD)

Characteristics

Feature	Description
Prevalence	1-3% of adults; 7-16% of adolescents
Sex ratio	Approximately equal
Typical onset	Adolescence or early adulthood
Social impact	School/work tardiness, conflict with morning obligations, academic underperformance
Circadian phase	Delayed (melatonin onset, body temperature minimum occur later)
Weekday vs weekend	Significant sleep extension on weekends (2-4 hours later wake times)

Diagnostic Criteria

Criterion	Description
A	Delayed sleep onset and wake times relative to desired times
B	Symptoms present for 3+ months
C	When allowed to sleep at desired times, sleep quality and duration are normal for age
D	At least 7 days of sleep log demonstrating delay (actigraphy preferred)
E	Not better explained by another sleep disorder, medical condition, or substance use

Treatment

Intervention	Protocol	Efficacy
Phase advance chronotherapy	Gradually advance bedtime by 1-2 hours daily until desired schedule achieved	Effective but difficult; requires strict adherence
Phase delay chronotherapy	Delay bedtime by 2-3 hours daily, moving forward around the clock (circadian 360-degree rotation)	Highly effective for DSWPD but disruptive; inpatient setting
Bright light therapy	30-60 minutes of 2,500-10,000 lux upon waking (immediately or within 30 min)	Moderate-high effect; consistent use critical
Melatonin (low-dose)	0.3-0.5 mg 5-6 hours before desired bedtime	Phase advances circadian clock; low dose avoids residual effects
Melatonin (moderate-dose)	1-3 mg approximately 2-3 hours before desired bedtime	May help sleep onset but higher risk of morning sedation
Combined therapy	Light + melatonin more effective than either alone	Standard of care
Maintaining schedule	Strictly enforced, including weekends	Essential for sustainability

Advanced Sleep-Wake Phase Disorder (ASWPD)

Characteristics

Feature	Description
Prevalence	<1% of adults; may be more common in elderly
Typical presentation	Unable to stay awake until conventional bedtime, waking earlier than desired
Circadian phase	Advanced (melatonin and temperature rhythm occur earlier)
Social impact	Missed evening social engagements, difficulty with night work
Genetic component	Familial forms associated with PER2, CK1delta mutations

Treatment

Intervention	Protocol	Efficacy
Phase delay chronotherapy	Gradually delay bedtime by 1-2 hours daily	Effective but requires strict adherence
Evening bright light therapy	2,000-10,000 lux for 1-2 hours in early evening (7-9 PM)	Moderate; phase delays the clock
Melatonin	Low dose (0.3-0.5 mg) upon early morning awakening	May help phase delay
Structured evening activities	Encourage staying awake until desired bedtime	Behavioral/lifestyle modification

Shift Work Disorder

Prevalence and Impact

Aspect	Data
Workforce percentage	Approximately 15-25% of workers engage in shift work
Affected workers	10-40% of night shift workers meet criteria for shift work disorder
Health consequences	Increased risk of cardiovascular disease, metabolic syndrome, cancer (breast, prostate), obesity, diabetes, gastrointestinal disorders
Safety consequences	Increased workplace accidents, motor vehicle accidents (2-3x on commute home after night shift)
Economic impact	Estimated $100-300 billion/year in lost productivity and health costs

Diagnosis

Criterion	Description
A	Insomnia or excessive sleepiness temporally associated with shift work schedule
B	Present for 3+ months
C	Sleep log/actigraphy for 14+ days demonstrates circadian misalignment
D	Not better explained by another sleep or medical disorder

Treatment Strategies

Intervention	Timing	Evidence
Strategic napping	20-30 minutes before shift or during break	Improves alertness
Bright light during shift	2,000-10,000 lux during first part of night shift	Facilitates circadian adaptation
Blue-blocking glasses	Wear on commute home (morning)	Prevents alerting light from re-entraining to daytime
Dark bedroom	Blackout curtains, no light exposure during daytime sleep	Promotes daytime sleep quality
Melatonin	0.5-3 mg before daytime sleep	May improve daytime sleep duration
Fixed shift schedule	Forward rotation (morning-evening-night) preferred to backward	Better adaptation
Avoid	Quick shift rotations (<7 days), backward rotation	Increases circadian misalignment
Caffeine	Only during first half of shift	Maintains alertness without affecting post-shift sleep

Shift Work Sleep Strategies by Schedule Type

Schedule	Sleep Strategy
Permanent night shift	Maintain consistent daytime sleep schedule even on days off
Rotating (forward)	Use bright light on first night shift, dark bedroom after
Rotating (backward)	Avoid if possible; if not, use strict timing of light exposure
Early morning shift	Early bedtime (8-9 PM), bright light on awakening, brief nap before work
On-call	Sleep whenever possible; prioritize sleep over non-essential activities

Jet Lag Disorder

Pathophysiology

Factor	Contribution
Number of time zones crossed	Approximate adaptation: 1 day per time zone (eastward), 1 day per 1.5 time zones (westward)
Direction of travel	Eastward harder (requires phase advance) than westward (requires phase delay)
Light exposure at destination	Inappropriate light at destination can entrain to wrong phase
Individual factors	Morningness-eveningness preference, age, flexibility of schedule

Symptoms

Symptom	Frequency
Daytime fatigue	90%+
Difficulty initiating or maintaining sleep	80-90%
Impaired concentration	70-80%
GI symptoms (appetite loss, indigestion, altered bowel function)	40-60%
Generalized malaise	60-70%
Mood changes (irritability, mild depression)	40-50%

Prevention and Treatment

Strategy	Eastbound (Phase Advance)	Westbound (Phase Delay)
Pre-travel adjustment	Advance bedtime 30 min/day for 3-4 days before travel	Delay bedtime 30 min/day for 3-4 days
Light exposure at destination	Seek bright light in morning; avoid light in evening	Seek bright light in evening; avoid light in morning
Melatonin	0.5-5 mg at target destination bedtime	Same (take at local bedtime)
Timing of arrival	Early morning arrival facilitates adjustment	Evening arrival
Caffeine	Strategic use in mornings only	Strategic use in first part of day
Meals	Eat meals according to destination schedule	Eat according to local time
Hydration	Drink water during flight, avoid alcohol and caffeine	Same
Exercise	Light exercise at appropriate time promotes adaptation	Same

Jet Lag Medications

Agent	Dose	Timing	Evidence
Melatonin	0.5-5 mg	Destination bedtime	Strong evidence for sleep onset
Melatonin + light therapy	As above	At targeted times	Superior to either alone
Zolpidem	5-10 mg	Destination bedtime	Moderate evidence for sleep maintenance
Modafinil	200 mg	Morning at destination	Improves wakefulness (not approved specifically for jet lag)
Armodafinil	150 mg	Morning	Same as modafinil
Ramelteon	8 mg	Bedtime	Limited evidence specifically for jet lag

Non-24-Hour Sleep-Wake Rhythm Disorder

Characteristics

Aspect	Details
Prevalence	50-70% of blind individuals; rare in sighted
Mechanism	Lack of photic entrainment (blind); in sighted, exposure to bright light at wrong circadian time
Pattern	Progressive delay of sleep-wake cycle (typically 30-60 minutes per day)
Symptoms	Cycling periods of good sleep (when aligned) alternating with poor sleep (when misaligned)

Treatment

Strategy	Blind Individuals	Sighted Individuals
Melatonin	Low dose (0.5 mg) at fixed time daily	Same
Tasimelteon (Hetlioz)	FDA-approved (20 mg at bedtime)	Off-label
Light therapy	Not applicable	Structured bright light at appropriate circadian times
Behavioral	Strict fixed wake time	Structured schedule with appropriate light exposure

Irregular Sleep-Wake Rhythm Disorder

Characteristics

Aspect	Details
Prevalence	Common in dementia, traumatic brain injury, neurodevelopmental disorders
Pattern	At least 3 periods of sleep and wake within 24 hours
Total sleep	Normal for age but fragmented into multiple bouts
Circadian rhythm	Absent or very weak (low amplitude)

Treatment

Intervention	Rationale	Evidence
Bright light therapy (morning)	Strengthen circadian signal	Moderate in dementia
Structured daytime activities	Consolidate wakefulness	Supportive
Sleep hygiene	Consolidate nighttime sleep	Supportive
Melatonin (evening)	If circadian disruption	Variable evidence
Avoid sedatives	May worsen fragmentation	Recommendation

Light Therapy Protocols

Devices and Dosing

Device Type	Typical Output	Indications
Light box (standard)	10,000 lux at 12-18 inches	DSWPD, ASWPD, shift work, SAD
Light box (compact)	5,000-10,000 lux	Portable use
Dawn simulator	Gradual light increase over 30-60 min before wake	ASWPD, winter depression
Blue light device	460-480 nm, lower intensity	Compact, potentially more effective per unit intensity

Timing Guidelines

Disorder	Light Exposure Time	Duration	Intensity
DSWPD	Immediately upon desired wake time	30-60 min	2,500-10,000 lux
ASWPD	Early evening (7-9 PM)	60-120 min	2,000-10,000 lux
Night shift adaptation	During first 4-6 hours of shift	Duration varies	2,000-10,000 lux
Jet lag (eastbound)	Morning at destination (10 AM-12 PM)	30-60 min	2,000-10,000 lux
Jet lag (westbound)	Late afternoon-evening at destination	30-60 min	2,000-10,000 lux
Non-24	Morning	60-90 min	5,000-10,000 lux
SAD (winter depression)	Morning	30-60 min	10,000 lux

Chronotherapy

Types of Chronotherapy

Type	Method	Best For	Difficulty
Phase advance	Gradually move bedtime earlier by 15-30 min per night	DSWPD (small advances)	Moderate
Phase delay (circadian rotation)	Move bedtime 2-3 hours later each day, going around the clock	DSWPD, Non-24	High (requires 1-2 weeks)
Phase delay (conventional)	Gradually delay bedtime by 15-30 min per night	ASWPD	Moderate
Reset protocol	Sleep deprivation + timed light exposure	Severe phase disorders	High

Circadian Rotation (for DSWPD)

Day	Desired Bedtime	Desired Wake Time
Baseline	3 AM	11 AM
Day 1	6 AM	2 PM
Day 2	9 AM	5 PM
Day 3	12 PM	8 PM
Day 4	3 PM	11 PM
Day 5	6 PM	2 AM
Day 6	9 PM	5 AM
Day 7 (target)	11 PM	7 AM

Melatonin in Circadian Disorders

Melatonin Timing by Therapeutic Goal

Goal	Timing	Dose	Rationale
Phase advance	5-6 hours before desired bedtime	0.3-0.5 mg	Advances (shifts earlier) circadian clock
Phase delay	2-3 hours before desired wake time	0.3-0.5 mg	Delays (shifts later) circadian clock
Sleep induction (hypnotic)	At bedtime	3-5 mg	High dose may promote sleep onset but less circadian effect
Circadian entrainment (blind)	Fixed time daily	0.5 mg	Consistent timing entrains free-running rhythm
Shift work	Before daytime sleep	1-3 mg	May improve daytime sleep quality

Assessment Tools

Circadian Phase Assessment

Method	Gold Standard	Practicality
Dim light melatonin onset (DLMO)	Yes	Requires saliva/blood samples in dim light every 30 min for 4-6 hours
Core body temperature minimum	Yes	Continuous rectal temperature monitoring
24-hour urinary 6-sulfatoxymelatonin	Moderate	Collection over 24-48 hours
Morningness-Eveningness Questionnaire (MEQ)	No (self-report)	Established psychometric properties; 19 items
Munich Chronotype Questionnaire (MCTQ)	No (self-report)	Assesses actual sleep timing on work vs free days
Sleep log (1-2 weeks)	No (behavioral)	Useful for capturing sleep-wake pattern
Actigraphy	No (behavioral)	Objective measure of rest-activity pattern

Morningness-Eveningness Questionnaire (MEQ) Categories

Score	Chronotype	Characteristics
16-30	Definitely evening type	Peak alertness in evening; prefer late bedtime/wake
31-41	Moderately evening type	Moderate evening preference
42-58	Neither type	Intermediate chronotype
59-69	Moderately morning type	Moderate morning preference
70-86	Definitely morning type	Peak alertness in morning; prefer early bedtime/wake